Tremfya vs. Dupixent

Tremfya (guselkumab) injection and Dupixent (dupilumab) injection are monoclonal antibodies used to treat different skin conditions.

Tremfya is used to treat adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Dupixent is used to treat adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Side effects of Tremfya and Dupixent that are similar include injection site reactions and herpes simplex infections.

Side effects of Tremfya that are different from Dupixent include upper respiratory infections, headache, joint pain, diarrhea, gastroenteritis (nausea, vomiting, diarrhea, cramps, and fever), and tinea infections (athlete's foot, ringworm, jock itch).

Side effects of Dupixent that are different from Tremfya include pink eye (conjunctivitis), swollen or puffy eyelids, inflammation of the cornea (keratitis), eye itching, and dry eye.

Both Tremfya and Dupixent may interact with "live" vaccines.

Tremfya may also interact with CYP450 substrates.

Dupixent may also interact with warfarin and cyclosporine.

Common side effects of Tremfya include:

• upper respiratory infections,
• headache,
• injection site reactions,
• joint pain,
• diarrhea,
• gastroenteritis (nausea, vomiting, diarrhea, cramps, and fever),
• tinea infections (athlete's foot, ringworm, jock itch), and
• herpes simplex infections

Common side effects of Dupixent include:

• injection site reactions,
• pink eye (conjunctivitis),
• swollen or puffy eyelids,
• oral herpes,
• inflammation of the cornea (keratitis),
• eye itching,
• other herpes simplex virus infection, and
• dry eye.

Tremfya (guselkumab) injection, for subcutaneous use is an interleukin-23 blocker indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Dupixent (dupilumab) injection is aninterleukin-4 receptor alpha-antagonist indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

Tremfya may interact with "live" vaccines and CYP450 substrates. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Tremfya; it is unknown how it would affect a fetus. Human IgG antibodies are known to cross the placental barrier; therefore, Tremfya may be transmitted from the mother to the developing fetus. It is unknown if Tremfya passes into breast milk. Consult your doctor before breastfeeding.

Dupixent may interact with “live” vaccines, warfarin, or cyclosporine. Tell your doctor all medications and supplements you use and all vaccines you recently received.

The dose of Tremfya is 100 mg administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter.

The recommended dose of Dupixent is an initial dose of 600 mg (two 300 mg injections in different injection sites), followed by 300 mg given every other week.